PROPANC BIOPHARMA, INC.
302, 6 Butler Street
Camberwell, VIC, 3124 Australia
October 26, 2018
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Propanc Biopharma, Inc. |
| Registration Statement on Form S-1 | |
| File No. 333-227877 |
Ladies and Gentleman:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Propanc Biopharma, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated so that it will become effective at 10:00 A.M. Eastern Time on Tuesday, October 30, 2018, or as soon as practicable thereafter.
We request that we be notified of such effectiveness by a telephone call to Jonathan Shechter of Foley Shechter LLP at (212) 335-0465, or in his absence Sasha Ablovatskiy of Foley Shechter LLP at (212) 335-0466. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of such Registration Statement be sent to Foley Shechter LLP, attention: Jonathan Shechter, via facsimile at (917) 688-4092.
| Sincerely, | ||
| PROPANC BIOPHARMA, INC. | ||
| By: | /s/ James Nathanielsz | |
| Name: | James Nathanielsz | |
| Title: | Chief Executive Officer and Chief Financial Officer | |
| Cc: | Jonathan Shechter, Foley Shechter LLP |
| Sasha Ablovatskiy, Foley Shechter LLP |